23 celebrities who've opened up about taking Ozempic or weight-loss drugs
As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.
Wall Street Journal12d
Why Novo Nordisk’s Stock Plunge Rattled Markets Today
Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.
New York Post14d
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Money Morning14d
Novo Nordisk Faces 20-Year Worst Stock Drop: Bear Market Price Target Revealed
Novo Nordisk (NVO) stock dropped more than 15% on Friday following an update on its obesity drug that fell short of expectations. Headlines from the company’s press release revealed that Novo ...
CNN14d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...
Yahoo Finance14d
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Bad news for Novo Nordisk (NYSE: NVO) Friday was good news for Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX), its two main rivals in the field of weight loss drugs. This morning ...
Ekstra Bladet14d
Novo Nordisk ramt af største aktienedtur siden 2002
Skuffende data for vægttabsmidlet Cagrisema sendte Novo Nordisk-aktien ned med 20,7 procent fredag Novo Nordisk-aktien styrdykkede med over 20 procent fredag efter offentliggørelsen af ...
Business Insider14d
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...
WISH-TV14d
Novo Nordisk’s new weight loss drug fails to surpass Lilly’s Zepbound
(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...
Business Insider14d
Jefferies Remains a Sell on Novo Nordisk (0QIU)
Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK575.00. The company’s shares closed yesterday at DKK743.20.
Channel NewsAsia Singapore14d
Weight-loss drugmaker Novo Nordisk's shares fall on disappointing study
COPENHAGEN: Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday (Dec 20) after it announced disappointing ...